BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 15548647)

  • 1. Chemotherapy for the brain: the antitumor antibiotic mithramycin prolongs survival in a mouse model of Huntington's disease.
    Ferrante RJ; Ryu H; Kubilus JK; D'Mello S; Sugars KL; Lee J; Lu P; Smith K; Browne S; Beal MF; Kristal BS; Stavrovskaya IG; Hewett S; Rubinsztein DC; Langley B; Ratan RR
    J Neurosci; 2004 Nov; 24(46):10335-42. PubMed ID: 15548647
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ESET/SETDB1 gene expression and histone H3 (K9) trimethylation in Huntington's disease.
    Ryu H; Lee J; Hagerty SW; Soh BY; McAlpin SE; Cormier KA; Smith KM; Ferrante RJ
    Proc Natl Acad Sci U S A; 2006 Dec; 103(50):19176-81. PubMed ID: 17142323
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modulation of nucleosome dynamics in Huntington's disease.
    Stack EC; Del Signore SJ; Luthi-Carter R; Soh BY; Goldstein DR; Matson S; Goodrich S; Markey AL; Cormier K; Hagerty SW; Smith K; Ryu H; Ferrante RJ
    Hum Mol Genet; 2007 May; 16(10):1164-75. PubMed ID: 17403718
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transgenic mice expressing mutated full-length HD cDNA: a paradigm for locomotor changes and selective neuronal loss in Huntington's disease.
    Reddy PH; Charles V; Williams M; Miller G; Whetsell WO; Tagle DA
    Philos Trans R Soc Lond B Biol Sci; 1999 Jun; 354(1386):1035-45. PubMed ID: 10434303
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Riluzole prolongs survival time and alters nuclear inclusion formation in a transgenic mouse model of Huntington's disease.
    Schiefer J; Landwehrmeyer GB; Lüesse HG; Sprünken A; Puls C; Milkereit A; Milkereit E; Kosinski CM
    Mov Disord; 2002 Jul; 17(4):748-57. PubMed ID: 12210870
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Remodeling of heterochromatin structure slows neuropathological progression and prolongs survival in an animal model of Huntington's disease.
    Lee J; Hwang YJ; Kim Y; Lee MY; Hyeon SJ; Lee S; Kim DH; Jang SJ; Im H; Min SJ; Choo H; Pae AN; Kim DJ; Cho KS; Kowall NW; Ryu H
    Acta Neuropathol; 2017 Nov; 134(5):729-748. PubMed ID: 28593442
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activation of NPY-Y2 receptors ameliorates disease pathology in the R6/2 mouse and PC12 cell models of Huntington's disease.
    Fatoba O; Kloster E; Reick C; Saft C; Gold R; Epplen JT; Arning L; Ellrichmann G
    Exp Neurol; 2018 Apr; 302():112-128. PubMed ID: 29309751
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Paradoxical delay in the onset of disease caused by super-long CAG repeat expansions in R6/2 mice.
    Morton AJ; Glynn D; Leavens W; Zheng Z; Faull RL; Skepper JN; Wight JM
    Neurobiol Dis; 2009 Mar; 33(3):331-41. PubMed ID: 19130884
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Partial resistance to malonate-induced striatal cell death in transgenic mouse models of Huntington's disease is dependent on age and CAG repeat length.
    Hansson O; Castilho RF; Korhonen L; Lindholm D; Bates GP; Brundin P
    J Neurochem; 2001 Aug; 78(4):694-703. PubMed ID: 11520890
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic effects of coenzyme Q10 and remacemide in transgenic mouse models of Huntington's disease.
    Ferrante RJ; Andreassen OA; Dedeoglu A; Ferrante KL; Jenkins BG; Hersch SM; Beal MF
    J Neurosci; 2002 Mar; 22(5):1592-9. PubMed ID: 11880489
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neuroprotective effects of creatine in a transgenic mouse model of Huntington's disease.
    Ferrante RJ; Andreassen OA; Jenkins BG; Dedeoglu A; Kuemmerle S; Kubilus JK; Kaddurah-Daouk R; Hersch SM; Beal MF
    J Neurosci; 2000 Jun; 20(12):4389-97. PubMed ID: 10844007
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment with a herbal formula B401 enhances neuroprotection and angiogenesis in the R6/2 mouse model of Huntington's disease.
    Wang SE; Lin CL; Hsu CH; Sheu SJ; Chien CT; Wu CH
    Drug Des Devel Ther; 2015; 9():887-900. PubMed ID: 25733809
    [TBL] [Abstract][Full Text] [Related]  

  • 13. AMPK-α1 functions downstream of oxidative stress to mediate neuronal atrophy in Huntington's disease.
    Ju TC; Chen HM; Chen YC; Chang CP; Chang C; Chern Y
    Biochim Biophys Acta; 2014 Sep; 1842(9):1668-80. PubMed ID: 24946181
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The mGluR5 positive allosteric modulator, CDPPB, ameliorates pathology and phenotypic signs of a mouse model of Huntington's disease.
    Doria JG; de Souza JM; Andrade JN; Rodrigues HA; Guimaraes IM; Carvalho TG; Guatimosim C; Dobransky T; Ribeiro FM
    Neurobiol Dis; 2015 Jan; 73():163-73. PubMed ID: 25160573
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of the Huntington's disease transgene in neural stem cell cultures from R6/2 transgenic mice.
    Chu-LaGraff Q; Kang X; Messer A
    Brain Res Bull; 2001 Oct-Nov 1; 56(3-4):307-12. PubMed ID: 11719265
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Histone deacetylase inhibition by sodium butyrate chemotherapy ameliorates the neurodegenerative phenotype in Huntington's disease mice.
    Ferrante RJ; Kubilus JK; Lee J; Ryu H; Beesen A; Zucker B; Smith K; Kowall NW; Ratan RR; Luthi-Carter R; Hersch SM
    J Neurosci; 2003 Oct; 23(28):9418-27. PubMed ID: 14561870
    [TBL] [Abstract][Full Text] [Related]  

  • 17. N-Acetylcysteine improves mitochondrial function and ameliorates behavioral deficits in the R6/1 mouse model of Huntington's disease.
    Wright DJ; Renoir T; Smith ZM; Frazier AE; Francis PS; Thorburn DR; McGee SL; Hannan AJ; Gray LJ
    Transl Psychiatry; 2015 Jan; 5(1):e492. PubMed ID: 25562842
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Striatal phosphodiesterase mRNA and protein levels are reduced in Huntington's disease transgenic mice prior to the onset of motor symptoms.
    Hebb AL; Robertson HA; Denovan-Wright EM
    Neuroscience; 2004; 123(4):967-81. PubMed ID: 14751289
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Altered histone monoubiquitylation mediated by mutant huntingtin induces transcriptional dysregulation.
    Kim MO; Chawla P; Overland RP; Xia E; Sadri-Vakili G; Cha JH
    J Neurosci; 2008 Apr; 28(15):3947-57. PubMed ID: 18400894
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression, pharmacology and functional activity of adenosine A1 receptors in genetic models of Huntington's disease.
    Ferrante A; Martire A; Pepponi R; Varani K; Vincenzi F; Ferraro L; Beggiato S; Tebano MT; Popoli P
    Neurobiol Dis; 2014 Nov; 71():193-204. PubMed ID: 25132555
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.